Thasarat Sutabutr Vajaranant
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Thasarat Sutabutr Vajaranant has a total of 116 co-authors. Here are the top co-authors by number of shared publications:
Mary N. Haan
Department of Epidemiology and Biostatistics (M.N.H.), University of California at San Francisco, San Francisco, California, USA
6 shared publicationsJacob T Wilensky
Department of Ophthalmology and Visual Sciences, Illinois Eye and Ear Infirmary, University of Illinois at Chicago, Chicago, IL, USA
5 shared publicationsLouis R. Pasquale
Affiliation Department of Ophthalmology, Icahn School of Medicine at Mount Sinai, New York, New York, United States of America
5 shared publicationsAbhishek Sethi
Illinois Eye and Ear Infirmary, Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, USA
4 shared publicationsJacob T. Wilensky
Illinois Eye and Ear Infirmary, Department of Ophthalmology and Visual Sciences, University of Illinois, Chicago, Ill
4 shared publicationsPauline M. Maki
Department of Psychiatry (P.M.M.), University of Illinois at Chicago, Chicago, Illinois, USA
4 shared publications
Latest Publications
- Open Access
- 1 February 2025
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 105, 101336
Comparative insights into the role of sex hormones in glaucoma among women and men
- 1 February 2025
- Published by Elsevier in Progress in Retinal and Eye Research
- Vol. 105, 101336
Open AccessComparative insights into the role of sex hormones in glaucoma among women and men
- 26 September 2024
- Published by Springer Nature in Eye
- Vol. 38 (18) , 3409-3411
Melatonin as an adjuvant: reshaping glaucoma treatment strategies
- 26 September 2024
- Published by Springer Nature in Eye
- Vol. 38 (18) , 3409-3411
Melatonin as an adjuvant: reshaping glaucoma treatment strategies
- 6 September 2023
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 34 (2) , 471-479
Pregnancy outcomes in the medical management of glaucoma: An international multicenter descriptive survey
Purpose: To determine if glaucoma medications are associated with pregnancy and/or postnatal complications. Methods: Multicenter descriptive survey. Subjects were female patients 18–45 years who were previously pregnant with a diagnosis of glaucoma or ocular hypertension prior to pregnancy. Chart review queried diagnosis, glaucoma severity, and race. Survey questions were asked for each pregnancy and queried pregnancy age, medications used, and pregnancy outcomes/complications. Results: 114 pregnancies of 56 patients (mean 2.0 pregnancies per patient) were included. Three pregnancies with therapeutic abortion were excluded from further analysis. Mean age during pregnancy was 29.1 ± 5.7 years. Of the 111 pregnancies, 20 (18.0%) used no medications and 91 (82.0%) used at least one medication. Medications were topical carbonic anhydrase inhibitors (n = 45), beta-blockers (n = 55), alpha-agonists (n = 56), and prostaglandin analogues (n = 28). Outcomes were: preterm contractions/labour (6.3%), miscarriage (4.5%), stillbirth (4.5%), induction of labour (11.9%), emergency/unplanned caesarean delivery (13.9%), neonatal intensive care unit (NICU) stay (15.8%), congenital anomalies (8.1%), and low birth weight (10.9%). Fisher exact test assessed outcome associations with individual agents, use of any agent, and different number of agents. Alpha-agonist use was associated with NICU stay: 25.5% rate ( p = 0.012) in alpha-agonist use. Most of the alpha-agonist use NICU stays occurred in pregnancies with third trimester use. All other associations were not statistically significant. Conclusions: The data from this survey suggest an overall favourable safety profile for topical glaucoma medications in pregnancy, but further investigation is needed. Caution should be employed regarding third trimester alpha-agonist use owing to association with NICU stay.
- 6 September 2023
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 34 (2) , 471-479
Pregnancy outcomes in the medical management of glaucoma: An international multicenter descriptive survey
Purpose: To determine if glaucoma medications are associated with pregnancy and/or postnatal complications. Methods: Multicenter descriptive survey. Subjects were female patients 18–45 years who were previously pregnant with a diagnosis of glaucoma or ocular hypertension prior to pregnancy. Chart review queried diagnosis, glaucoma severity, and race. Survey questions were asked for each pregnancy and queried pregnancy age, medications used, and pregnancy outcomes/complications. Results: 114 pregnancies of 56 patients (mean 2.0 pregnancies per patient) were included. Three pregnancies with therapeutic abortion were excluded from further analysis. Mean age during pregnancy was 29.1 ± 5.7 years. Of the 111 pregnancies, 20 (18.0%) used no medications and 91 (82.0%) used at least one medication. Medications were topical carbonic anhydrase inhibitors (n = 45), beta-blockers (n = 55), alpha-agonists (n = 56), and prostaglandin analogues (n = 28). Outcomes were: preterm contractions/labour (6.3%), miscarriage (4.5%), stillbirth (4.5%), induction of labour (11.9%), emergency/unplanned caesarean delivery (13.9%), neonatal intensive care unit (NICU) stay (15.8%), congenital anomalies (8.1%), and low birth weight (10.9%). Fisher exact test assessed outcome associations with individual agents, use of any agent, and different number of agents. Alpha-agonist use was associated with NICU stay: 25.5% rate ( p = 0.012) in alpha-agonist use. Most of the alpha-agonist use NICU stays occurred in pregnancies with third trimester use. All other associations were not statistically significant. Conclusions: The data from this survey suggest an overall favourable safety profile for topical glaucoma medications in pregnancy, but further investigation is needed. Caution should be employed regarding third trimester alpha-agonist use owing to association with NICU stay.
- Open Access
- 3 May 2023
- Published by Springer Nature in Eye
- Vol. 37 (17) , 3523-3525
Which OCT parameters can best predict visual field progression in glaucoma?
- 3 May 2023
- Published by Springer Nature in Eye
- Vol. 37 (17) , 3523-3525
Open AccessWhich OCT parameters can best predict visual field progression in glaucoma?
- 27 February 2023
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 33 (5) , 1969-1976
Topical netarsudil for treatment of glaucoma with elevated episcleral venous pressure: A pilot investigation in sturge-weber syndrome
Purpose: Topical netarsudil 0.02% may reduce intraocular pressure (IOP) by decreasing episcleral venous pressure (EVP), which carries theoretical utility for glaucoma associated with elevated EVP. A role for netarsudil in patients with elevated EVP is evaluated in a pilot investigation using a cohort of individuals with Sturge-Weber syndrome (SWS). Methods: Retrospective study of patients with SWS and glaucoma who were treated with netarsudil. Five patients (six eyes) were identified. Data collected included demographics, visual acuity, IOP, glaucoma medical and surgical treatments, and adverse effects of netarsudil. Results: Mean age was 13.6 ± 8.5 years. EVP elevation was presumed based on clinical stigmata and/or historical features. Mean number of baseline glaucoma medications was 3.3 ± 1.2. There was a significant reduction in the IOP at netarsudil initiation (mean 26.2 ± 4.5 mmHg) to 1 month of netarsudil therapy (mean 20.2 ± 3.8 mmHg, p = 0.0283 ) and latest IOP on netarsudil (mean 17.6 ± 1.4 mmHg, p = 0.0034). Mean duration of netarsudil therapy was 18.7 ± 11.8 months. Three patients required additional glaucoma procedures; one patient required an additional glaucoma medication. Three eyes (50%) developed conjunctival hyperemia. One patient discontinued netarsudil at 29 months, to reduce drop burden. Conclusions: Netarsudil can effectively reduce IOP in patients with SWS, even when used as a fourth or fifth glaucoma medication. A possible role for netarsudil in the management of patients with elevated EVP is suggested pending further future investigations.
- 27 February 2023
- Published by SAGE Publications in European Journal of Ophthalmology
- Vol. 33 (5) , 1969-1976
Topical netarsudil for treatment of glaucoma with elevated episcleral venous pressure: A pilot investigation in sturge-weber syndrome
Purpose: Topical netarsudil 0.02% may reduce intraocular pressure (IOP) by decreasing episcleral venous pressure (EVP), which carries theoretical utility for glaucoma associated with elevated EVP. A role for netarsudil in patients with elevated EVP is evaluated in a pilot investigation using a cohort of individuals with Sturge-Weber syndrome (SWS). Methods: Retrospective study of patients with SWS and glaucoma who were treated with netarsudil. Five patients (six eyes) were identified. Data collected included demographics, visual acuity, IOP, glaucoma medical and surgical treatments, and adverse effects of netarsudil. Results: Mean age was 13.6 ± 8.5 years. EVP elevation was presumed based on clinical stigmata and/or historical features. Mean number of baseline glaucoma medications was 3.3 ± 1.2. There was a significant reduction in the IOP at netarsudil initiation (mean 26.2 ± 4.5 mmHg) to 1 month of netarsudil therapy (mean 20.2 ± 3.8 mmHg, p = 0.0283 ) and latest IOP on netarsudil (mean 17.6 ± 1.4 mmHg, p = 0.0034). Mean duration of netarsudil therapy was 18.7 ± 11.8 months. Three patients required additional glaucoma procedures; one patient required an additional glaucoma medication. Three eyes (50%) developed conjunctival hyperemia. One patient discontinued netarsudil at 29 months, to reduce drop burden. Conclusions: Netarsudil can effectively reduce IOP in patients with SWS, even when used as a fourth or fifth glaucoma medication. A possible role for netarsudil in the management of patients with elevated EVP is suggested pending further future investigations.
- 10 January 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 249, 21-28
An Association Between Large Optic Cupping and Total and Regional Brain Volume: The Women's Health Initiative
- 10 January 2023
- Published by Elsevier in American Journal of Ophthalmology
- Vol. 249, 21-28
An Association Between Large Optic Cupping and Total and Regional Brain Volume: The Women's Health Initiative
- 21 November 2022
- Published by Elsevier in Ophthalmology
- Vol. 130 (6) , 565-574
Effect of Low-Fat Dietary Modification on Incident Open-Angle Glaucoma
- 21 November 2022
- Published by Elsevier in Ophthalmology
- Vol. 130 (6) , 565-574
Effect of Low-Fat Dietary Modification on Incident Open-Angle Glaucoma
- Open Access
- 31 October 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (10) , e0258564
Association between cognitive function and large optic nerve cupping, accounting for cup-disc-ratio genetic risk score
Purpose: To investigate if accounting for a cup-to-disc ratio (CDR) genetic risk score (GRS) modified the association between large CDR and cognitive function among women. Design: This was a retrospective study using data from the Women’s Health Initiative. Methods: Patients with glaucoma or ocular hypertension were excluded. Large CDR was defined as ≥ 0.6 in either eye. Cognitive function was measured by the Modified Mini-Mental State Examination (3MSE). We used the combined effects from 13 single nucleotide polymorphisms (SNPs) to formulate the GRS for CDR. We used logistic regression to investigate associations between weighted GRS and large CDR, then a linear regression to assess the association between weighted GRS and 3MSE scores, and between weighted GRS, CDR, and 3MSE scores, adjusted for demographic and clinical characteristics. Results: Final analyses included 1,196 White women with mean age of 69.60 ± 3.62 years and 7.27% with large CDR. Mean GRS in women with and without large CDR was 1.51 ± 0.31 vs. 1.41 ± 0.36, respectively (p = 0.004). The odds of large CDR for a one unit increase in GRS was 2.30 (95% CI: (1.22, 4.36), p = 0.011). Adding the CDR GRS in the model with CDR and 3MSE, women with large CDR still had statistically significantly lower 3MSE scores than those without large CDR, yielding a predicted mean difference in 3MSE scores of 0.84 (p = 0.007). Conclusions: Independent of the CDR GRS, women with large CDR had a lower cognitive function.
- 31 October 2022
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 17 (10) , e0258564
Open AccessAssociation between cognitive function and large optic nerve cupping, accounting for cup-disc-ratio genetic risk score
Purpose: To investigate if accounting for a cup-to-disc ratio (CDR) genetic risk score (GRS) modified the association between large CDR and cognitive function among women. Design: This was a retrospective study using data from the Women’s Health Initiative. Methods: Patients with glaucoma or ocular hypertension were excluded. Large CDR was defined as ≥ 0.6 in either eye. Cognitive function was measured by the Modified Mini-Mental State Examination (3MSE). We used the combined effects from 13 single nucleotide polymorphisms (SNPs) to formulate the GRS for CDR. We used logistic regression to investigate associations between weighted GRS and large CDR, then a linear regression to assess the association between weighted GRS and 3MSE scores, and between weighted GRS, CDR, and 3MSE scores, adjusted for demographic and clinical characteristics. Results: Final analyses included 1,196 White women with mean age of 69.60 ± 3.62 years and 7.27% with large CDR. Mean GRS in women with and without large CDR was 1.51 ± 0.31 vs. 1.41 ± 0.36, respectively (p = 0.004). The odds of large CDR for a one unit increase in GRS was 2.30 (95% CI: (1.22, 4.36), p = 0.011). Adding the CDR GRS in the model with CDR and 3MSE, women with large CDR still had statistically significantly lower 3MSE scores than those without large CDR, yielding a predicted mean difference in 3MSE scores of 0.84 (p = 0.007). Conclusions: Independent of the CDR GRS, women with large CDR had a lower cognitive function.
- 1 June 2022
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 140 (6) , 637-638
Clinical Dilemma—Topical Prostaglandin Use in Glaucoma During Pregnancy
Glaucoma management during pregnancy presents a unique clinical challenge because of potential risks to the fetus and the lack of large-scale safety and efficacy data on glaucoma treatment in this population.1 A 2007 survey conducted in the United Kingdom indicates uncertainty among ophthalmologists regarding glaucoma management during pregnancy.2 Approximately one-third of the responding ophthalmologists reported having experiences treating patients with glaucoma during pregnancy. When the ophthalmologists were asked about their treatment choices for patients with evidence of glaucoma progression during pregnancy, 31% stated that they were unsure about which treatment to use, 40% reported they would continue the prepregnancy treatment, and 17% noted they would continue observing the patient without prescribing treatment. In terms of medication choices, 45% chose topical β-blockers while 33% used topical prostaglandins. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.
- 1 June 2022
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 140 (6) , 637-638
Clinical Dilemma—Topical Prostaglandin Use in Glaucoma During Pregnancy
Glaucoma management during pregnancy presents a unique clinical challenge because of potential risks to the fetus and the lack of large-scale safety and efficacy data on glaucoma treatment in this population.1 A 2007 survey conducted in the United Kingdom indicates uncertainty among ophthalmologists regarding glaucoma management during pregnancy.2 Approximately one-third of the responding ophthalmologists reported having experiences treating patients with glaucoma during pregnancy. When the ophthalmologists were asked about their treatment choices for patients with evidence of glaucoma progression during pregnancy, 31% stated that they were unsure about which treatment to use, 40% reported they would continue the prepregnancy treatment, and 17% noted they would continue observing the patient without prescribing treatment. In terms of medication choices, 45% chose topical β-blockers while 33% used topical prostaglandins. Identify all potential conflicts of interest that might be relevant to your comment. Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued. Err on the side of full disclosure. If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response. Not all submitted comments are published. Please see our commenting policy for details.
- 23 April 2022
- Published by Springer Nature
- p. 719-734
Blunt Anterior Segment Trauma